Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01894672
Title BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan-Kettering Cancer Center
Indications

melanoma

Therapies

Encorafenib

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge New Jersey United States Details
Memorial Sloan Kettering Cancer Center at Commack Commack New York 11725 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Memorial Sloan Kettering Cancer Center at Mercy Medical Center Rockville Centre New York 11570 United States Details
Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center Sleepy Hollow New York 10591 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field